articleScienceJan 5, 2004Closed access

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Roche Pharma AG (Germany) · La Roche College

PubMed
Indexed incrossrefpubmed

Abstract

MDM2 binds the p53 tumor suppressor protein with high affinity and negatively modulates its transcriptional activity and stability. Overexpression of MDM2, found in many human tumors, effectively impairs p53 function. Inhibition of MDM2-p53 interaction can stabilize p53 and may offer a novel strategy for cancer therapy. Here, we identify potent and selective small-molecule antagonists of MDM2 and confirm their mode of action through the crystal structures of complexes. These compounds bind MDM2 in the p53-binding pocket and activate the p53 pathway in cancer cells, leading to cell cycle arrest, apoptosis, and growth inhibition of human tumor xenografts in nude mice.

Citation impact

4,661
total citations
FWCI
82.65
Percentile
100%
References
21
Citations per year

Authors

12

Topics & keywords

Keywords
  • Mdm2
  • Apoptosis
  • In vivo
  • Small molecule
  • Suppressor
  • Cancer research
  • Cell cycle checkpoint
  • Chemistry
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.